Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Oncotype DX Breast Cancer Assay

Known as: Oncotype DX 
A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
PURPOSE This focused update addresses the use of Oncotype DX in guiding decisions on the use of adjuvant systemic therapy… Expand
  • table 2
  • table 3
Is this relevant?
Review
2017
Review
2017
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is utilized in patients with… Expand
  • table 1
  • figure 1
Is this relevant?
2017
2017
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
PurposeOncotype DX (ODX) recurrence score (RS) breast cancer (BC) assay is costly, and performed in only ~1/3 of estrogen… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score
Oncotype DX (Genomic Health, Redwood City, CA, USA, current list price $4,350.00) is a multigene quantitative reverse… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
BACKGROUND We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by…
PURPOSE The Oncotype DX assay predicts likelihood of distant recurrence and improves patient selection for adjuvant chemotherapy… Expand
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?
Oncotype DXTM is an RT-PCR-based assay used to predict chemotherapy benefit in patients with estrogen receptor (ER) positive… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort
The use of clinicopathologic features in decision-making in early stage estrogen receptor (ER)-positive breast cancer (BC) may… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Trial assessing individualized options for treatment for breast cancer: the TAILORx trial.
Novel genetic profiling tests of breast cancer tissue have been shown to be prognostic for overall survival and predictive of… Expand
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX
  • V. Kaklamani
  • Expert review of molecular diagnostics
  • 2006
    • Corpus ID: 12514043
We now recognize that not all breast cancers are the same. Different characteristics in gene expression profiles result in… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE